| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/26/2009 | US20090081162 Method for downregulating an immune reaction |
| 03/26/2009 | US20090081161 Treatment of neoplasms with viruses |
| 03/26/2009 | US20090081160 Method for reducing the likelihood of implantation failure during an assisted reproduction in a subject |
| 03/26/2009 | US20090081159 Compositions and methods for detecting and treating ophthalmic disorders |
| 03/26/2009 | US20090081158 Phosphadiazine hcv polymerase inhibitors iv |
| 03/26/2009 | US20090081157 Immunostimulatory Combinations for Vaccine Adjuvants |
| 03/26/2009 | US20090081156 Bioactive molecular matrix and methods of use in the treatment of disease |
| 03/26/2009 | US20090081155 Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities |
| 03/26/2009 | US20090081144 Cosmetic compositions |
| 03/26/2009 | US20090081141 Topical use of thiazolidine derivatives against consequences of oxidative stress of skin |
| 03/26/2009 | US20090081139 Water-based delivery systems |
| 03/26/2009 | US20090081133 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations |
| 03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
| 03/26/2009 | US20090081125 Angiogenetic Agent Containing Adrenomedulin as the Active Ingredient |
| 03/26/2009 | US20090081124 Virus coat protein/receptor chimeras and methods of use |
| 03/26/2009 | CA2700115A1 Long interspersed nuclear element polypeptide compositions and methods of use thereof |
| 03/26/2009 | CA2699944A1 Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| 03/26/2009 | CA2699936A1 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| 03/26/2009 | CA2698814A1 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 03/26/2009 | CA2698293A1 Use of hydrophobin polypeptides as penetration intensifiers |
| 03/26/2009 | CA2698128A1 Use of g-csf for the treatment of stroke |
| 03/26/2009 | CA2697896A1 Ctl inducer composition |
| 03/25/2009 | EP2039773A1 Mutant vesicular stomatitis viruses and use thereof |
| 03/25/2009 | EP2039768A1 Mutant forms of Fas ligand and uses thereof |
| 03/25/2009 | EP2039764A1 Truncated secretory aspartyl proteinase 2 |
| 03/25/2009 | EP2039368A2 Methods for preventing reactivation of latent virus and controlling virus replication |
| 03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 03/25/2009 | EP2039366A1 Composition containing peptide as the active ingredient |
| 03/25/2009 | EP2039358A1 Pharmaceutical compositions comprising a macrolide and an acid |
| 03/25/2009 | EP2039357A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 03/25/2009 | EP2038654A1 Method of treating diseases with parp inhibitors |
| 03/25/2009 | EP2038415A1 Dph2 gene deletion mutant and uses thereof |
| 03/25/2009 | EP2038411A1 Modified beta-lactamase and method for its preparation |
| 03/25/2009 | EP2038301A2 Compositions and methods for targeting cancer-specific transcription complexes |
| 03/25/2009 | EP2038297A1 Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease |
| 03/25/2009 | EP2037965A2 Pharmaceutical composition with synergistic anticonvulsant effect |
| 03/25/2009 | EP2037963A2 Soft tissue repair and regeneration using stem cell products |
| 03/25/2009 | EP2037956A2 Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative |
| 03/25/2009 | EP2037955A2 Recombinant or transgenic factor vii composition, each factor vii molecule having two n-glycosylation sites with defined glycan units |
| 03/25/2009 | EP2037954A2 Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| 03/25/2009 | EP2037953A2 Methods of treating acute blood loss anemia with a cross-linked hemoglobin blood substitute |
| 03/25/2009 | EP2037952A1 Vitreous administration of erythropoietin |
| 03/25/2009 | EP2037951A2 Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| 03/25/2009 | EP2037950A2 Further medical uses of antisecretory protein |
| 03/25/2009 | EP2037949A2 Transfer factor medicament - ways of manufacturing and use |
| 03/25/2009 | EP2037948A2 Detecting and treating dementia |
| 03/25/2009 | EP2037946A2 Phage derived antimicrobial activities |
| 03/25/2009 | EP2037945A2 Permeability of blood-brain barrier |
| 03/25/2009 | EP2037942A2 Polymeric biosurfactants |
| 03/25/2009 | EP2037737A2 Proteins, nucleic acids encoding the same and associated methods of use |
| 03/25/2009 | EP1945266A4 Methods of modulating apoptosis and platelet production using variants of cytochrome c |
| 03/25/2009 | EP1878454A9 Antihemorrhagic treatment kit |
| 03/25/2009 | EP1846445B1 Pyy agonists and uses thereof |
| 03/25/2009 | EP1824504B1 Antitumor combinations containing vegf-trap and 5fu or one of its derivatives |
| 03/25/2009 | EP1793859B1 Treatment of oral and intestinal mucositis by administering human il-18 |
| 03/25/2009 | EP1767626B1 Peroral vaccine carrier system |
| 03/25/2009 | EP1594523B1 Pharmaceutical compositions comprising botulinum toxin and human serum albumin |
| 03/25/2009 | EP1565206B1 Novel use of erythropoietin in heart diseases |
| 03/25/2009 | EP1543127B1 Nucleic acid sequences coding for proteolytic enzymes in the form of specific proteases, corresponding polypeptides and use of the same |
| 03/25/2009 | EP1353692B1 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 03/25/2009 | EP1242587B1 A NOVEL ISOFORM OF HUMAN cAMP-DEPENDENT PROTEIN KINASE, C ALPHA-s, LOCALIZES TO SPERM MIDPIECE AND THE USE THEREOF |
| 03/25/2009 | EP1221847B1 Methods of enhancing chemotherapy |
| 03/25/2009 | EP1053010B1 Copolymer compositions for oral delivery |
| 03/25/2009 | CN101395274A Chimeric Kunitz domains and their use |
| 03/25/2009 | CN101395268A Synergistic effect between a cyanogenic system and another oxidative inducer for the treatment of tumours |
| 03/25/2009 | CN101395263A Methods of making modular fusion protein expression products |
| 03/25/2009 | CN101395173A Template-fixed peptidomimetics with antimicrobial activity |
| 03/25/2009 | CN101395172A Novel antimicrobial peptides and use thereof |
| 03/25/2009 | CN101394863A Small-volume oral transmucosal dosage forms |
| 03/25/2009 | CN101394862A Treatment of HIV |
| 03/25/2009 | CN101394861A Extended release of neuregulin for improved cardiac function |
| 03/25/2009 | CN101394841A Fast-acting oral peptide pharmaceutical products |
| 03/25/2009 | CN101392262A Polypeptide of fungal ubuquitin-conjugating enzyme, coding sequence thereof and preparation method and application |
| 03/25/2009 | CN101392256A Gene synthesis of wild boar alpha-interferon, vector construction and method for producing outcome |
| 03/25/2009 | CN101392252A Lychas mucronatus Kv1.3 blocker gene, preparation method and application |
| 03/25/2009 | CN101392026A Polypeptide for preventing and treating fibrotic disease and liver cancer |
| 03/25/2009 | CN101392020A Musca domestic pupae natural antimicrobial peptide products and preparation method and use thereof |
| 03/25/2009 | CN101391105A Gene therapy for critical limb ischemia with wild type or mutant eNOS |
| 03/25/2009 | CN101391103A Medicine composition for preventing and treating AIDS viral infection |
| 03/25/2009 | CN101391101A New use of cyclodextrin glucanotransferase |
| 03/25/2009 | CN101391100A Use of recombined human source thioredoxin in preparing medicine for treating endotoxemia |
| 03/25/2009 | CN101391099A Use of growth hormone releasing peptides sustained release preparation in promoting fur-bearing animal grow |
| 03/25/2009 | CN101391098A Apitoxin liposome preparation and preparation method thereof |
| 03/25/2009 | CN101391097A Special short-chain peptide cancer therapeutical agent and use thereof in treating cancer |
| 03/25/2009 | CN101391096A Use of Staphylococcal Enterotoxin. C in preparing anti-tumor medicine |
| 03/25/2009 | CN101391095A Production technique of bone peptide calcium |
| 03/25/2009 | CN101390921A Composition of starwort total glycopeptides and total flavone and preparation method and uses thereof |
| 03/25/2009 | CN101390881A Preparation of wood louse powder extract and uses thereof |
| 03/25/2009 | CN101390880A Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure |
| 03/25/2009 | CN100472213C Detection and treatment of cancer |
| 03/25/2009 | CN100471873C A series of polypeptide capable of blocking IL-6 |
| 03/25/2009 | CN100471869C Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of coriolus versicolor |
| 03/25/2009 | CN100471868C Compositions and methods for WT1 specific immunotherapy |
| 03/25/2009 | CN100471521C Polypeptides having single covalently bound N-terminal water-soluble polymer |
| 03/25/2009 | CN100471486C Immunomodulatory compositions, methods of making, and methods of use thereof |
| 03/24/2009 | US7507872 Transgenic toll-like receptor 9 (TLR9) mice |
| 03/24/2009 | US7507807 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders |
| 03/24/2009 | US7507805 Cell death-inducing fused gene acting specifically on cancer and gene product thereof |
| 03/24/2009 | US7507801 therapies and screening methods for a variety of disorders including but not limited to: myeloid malignancies such as acute myelogenous leukemia, myelodysplastic syndrome, polycythemia vera and juvenile chronic myelogenous leukemia; autoimmune diso |
| 03/24/2009 | US7507799 High affinity ligand for p75 neurotrophin receptor |